Furthermore, ATL-146e reduced activated splenic CD4+ and CD8+ T cell numbers, decreased T cell infiltration into GVHD tissue, and reduced both weight loss and mortality in an allogeneic mouse model of GVHD. This evidence concerns the gene CD8A and graft versus host disease.